about
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosingToxic epidermal necrolysisPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewAssociation of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysisPharmacogenetics and individualizing drug treatment during pregnancy.Towards an ontological theory of substance intolerance and hypersensitivityMinocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae.A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.Pregnancy immunogenetics: NK cell education in the womb?A case of cholestatic hepatitis associated with histologic features of acute cholangitis.Complete haplotype phasing of the MHC and KIR loci with targeted HaploSeq.Ofloxacin Induced Cutaneous Reactions in Children.Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study.HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.The role of pharmacogenetics in treating central nervous system disorders.Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.Genetic predisposition of life-threatening antiepileptic-induced skin reactions.A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia.The genetics of antiepileptic drug-induced skin reactions.HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.Adverse cutaneous drug eruptions: current understanding.Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.Personalizing carbamazepine therapy.Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital.Update on the management of antibiotic allergy[DRESS syndrome. Rare and potentially lethal allergic reaction to carbamazepine - a case report].HLA typing in Brazilian boys with aromatic antiepileptic drug-induced DRESS.HLA*IMP--an integrated framework for imputing classical HLA alleles from SNP genotypes.Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions.ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response.Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine.A nested sequence-specific primer-polymerase chain reaction for the detection of HLA-B*15:02.Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.
P2860
Q24626941-A9AFB6A3-99E3-4986-B026-ACB157F8CBABQ26745232-81CF918A-37E9-466E-A0D3-34923C45E49FQ26797938-63A81596-876D-4B24-8DC0-51E4262FD83BQ26853305-6024B38D-3FB3-4489-A794-10492DB37622Q33781272-9C3751B3-E1AF-486E-BAF7-66569B82A488Q33925884-3F4B7794-5D7D-469B-A700-E80F893CE499Q34196966-BA7281EC-1CC5-459D-A5A5-3971855FEC22Q34215820-75A45723-CEB9-489A-9AA9-AC7E3211DBEDQ34245492-8621908B-EEEB-49E7-9DC7-C7D5B9F190F0Q35599972-8257F036-E9F1-4764-9D4F-26A94D47F79FQ35833809-5635B939-99FE-4B5E-8D70-72460DC4E00DQ35918110-41AD2EF7-BD12-4534-8AD5-2B114903C5ADQ36029478-122BBB6D-27B6-4CA1-AFFC-2EBC08DE4228Q36085404-0288278A-0BB8-4A7B-8730-1A5AD31475C7Q36413071-BD5B9D5B-8886-49E2-93B8-C62DB4300707Q36418662-8F8AFCF3-CE84-4A6B-ACE5-3AD191A46636Q37292132-54948039-DB65-4F99-8704-14D7287EC43CQ37335127-B4202178-65F0-4B0F-A49E-A7DE0EE5BE8BQ37650570-D9D7BEE4-F43B-468D-ADA2-1F454F9ED4A4Q37669205-DC006A4C-FADF-4D9C-968F-A4A8ACCA6859Q37859622-CD9278FE-94F8-40AE-9149-3C251A9FC6A0Q38058271-35DC0A04-D32E-440C-BADB-88AF26179021Q38219092-D1C5E6DE-E286-49BE-9174-973865BBE51BQ38222509-A4D7E4D4-E2A6-4B2F-8E11-DAD0BE942F0FQ38629246-976838EA-1545-42B3-916F-24F20C9C47A0Q38629821-C913CDC5-33E2-489F-9861-2C5F9948C5F4Q39190869-77F10BC5-EB6F-4750-AB4C-C0175D45B44FQ39382537-64929210-1214-4897-B04F-49FF5CF8F846Q39830842-709A57C6-900F-4FCE-9DF1-B62CA6E73543Q40244695-8F8A3004-A310-4B52-9EC3-1C6EC4823AC4Q40251537-447F2C6F-BBEC-4A2D-A967-C7A326F99118Q41920533-7208BF1C-3F1D-4D67-8442-0240F22B60BDQ41941729-A449CA0B-5F4E-4CC5-BA78-40C9692C52DAQ42025168-3E015A26-D030-4FA4-8E46-6132DD4B7FF1Q42925699-82E89389-B676-4098-AF99-A7B631D23AC9Q42974916-3C9D0892-680F-4777-B8A5-E3E63BC9BAB5Q43053794-F7FA5D64-9EE7-4288-8AD6-D3C0E4EDA507Q43162621-92CF0D6D-59A6-4A74-AFE5-5B7826771507Q44811148-18AC6707-544F-4C85-A70B-B11EC2ABBC0DQ46051781-D72237A8-402B-4329-85A4-34E49F4C780B
P2860
description
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im August 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: August 2007)
@en
vedecký článok (publikovaný 2007-08)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd in 2007-08)
@nl
наукова стаття, опублікована в серпні 2007
@uk
مقالة علمية (نشرت في أغسطس 2007)
@ar
name
Human leukocyte antigens and drug hypersensitivity
@ast
Human leukocyte antigens and drug hypersensitivity
@en
Human leukocyte antigens and drug hypersensitivity
@nl
type
label
Human leukocyte antigens and drug hypersensitivity
@ast
Human leukocyte antigens and drug hypersensitivity
@en
Human leukocyte antigens and drug hypersensitivity
@nl
prefLabel
Human leukocyte antigens and drug hypersensitivity
@ast
Human leukocyte antigens and drug hypersensitivity
@en
Human leukocyte antigens and drug hypersensitivity
@nl
P3181
P1476
Human leukocyte antigens and drug hypersensitivity
@en
P2093
Wen-Hung Chung
P304
P3181
P356
10.1097/ACI.0B013E3282370C5F
P407
P577
2007-08-01T00:00:00Z